These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 10898551)

  • 41. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
    Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
    Losa M; Garbin E; Pedone E; Mortini P
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
    Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
    Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
    Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
    Salvatori R; Nachtigall LB; Cook DM; Bonert V; Molitch ME; Blethen S; Chang S;
    Pituitary; 2010 Jun; 13(2):115-22. PubMed ID: 19898989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of acromegaly after octreotide LAR treatment.
    Mangupli R; Lisette A; Ivett C; Paul C; de los Ríos Victoria C; Luis CJ
    Pituitary; 2003; 6(1):29-34. PubMed ID: 14674721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.
    Lin JD; Lee ST; Weng HF
    Endocr J; 1999 Feb; 46(1):193-8. PubMed ID: 10426587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.
    Yetkin DO; Boysan SN; Tiryakioglu O; Yalin AS; Kadioglu P
    Endocr J; 2007 Jun; 54(3):459-64. PubMed ID: 17495423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
    Li ZQ; Quan Z; Tian HL; Cheng M
    J Int Med Res; 2012; 40(2):517-24. PubMed ID: 22613412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.
    Lombardi G; Minuto F; Tamburrano G; Ambrosio MR; Arnaldi G; Arosio M; Chiarini V; Cozzi R; Grottoli S; Mantero F; Bogazzi F; Terzolo M; Tita P; Boscani PF; Colao A
    J Endocrinol Invest; 2009 Mar; 32(3):202-9. PubMed ID: 19542735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CLINICAL OUTCOMES AND SELF-REPORTED SYMPTOMS IN PATIENTS WITH ACROMEGALY: AN 8-YEAR FOLLOW-UP OF A LANREOTIDE STUDY.
    Khairi S; Sagvand BT; Pulaski-Liebert KJ; Tritos NA; Klibanski A; Nachtigall LB
    Endocr Pract; 2017 Jan; 23(1):56-65. PubMed ID: 27682353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.